27 results on '"Narita, Yoshitaka"'
Search Results
2. Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma
- Author
-
Narita, Yoshitaka, Okita, Yoshiko, and Arakawa, Yoshiki
- Published
- 2022
- Full Text
- View/download PDF
3. MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
- Author
-
Hosoya, Tomohiro, Takahashi, Masamichi, Honda-Kitahara, Mai, Miyakita, Yasuji, Ohno, Makoto, Yanagisawa, Shunsuke, Omura, Takaki, Kawauchi, Daisuke, Tamura, Yukie, Kikuchi, Miyu, Nakano, Tomoyuki, Yoshida, Akihiko, Igaki, Hiroshi, Matsushita, Yuko, Ichimura, Koichi, and Narita, Yoshitaka
- Published
- 2022
- Full Text
- View/download PDF
4. The clinical characteristics and outcomes of incidentally discovered glioblastoma
- Author
-
Kawauchi, Daisuke, Ohno, Makoto, Honda-Kitahara, Mai, Miyakita, Yasuji, Takahashi, Masamichi, Yanagisawa, Shunsuke, Tamura, Yukie, Kikuchi, Miyu, Ichimura, Koichi, and Narita, Yoshitaka
- Published
- 2022
- Full Text
- View/download PDF
5. Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study
- Author
-
Aoki, Tomokazu, Kagawa, Naoki, Sugiyama, Kazuhiko, Wakabayashi, Toshihiko, Arakawa, Yoshiki, Yamaguchi, Shigeru, Tanaka, Shota, Ishikawa, Eiichi, Muragaki, Yoshihiro, Nagane, Motoo, Nakada, Mitsutoshi, Suehiro, Satoshi, Hata, Nobuhiro, Kuroda, Junichiro, Narita, Yoshitaka, Sonoda, Yukihiko, Iwadate, Yasuo, Natsumeda, Manabu, Nakazato, Yoichi, Minami, Hironobu, Hirata, Yuki, Hagihara, Shunsuke, and Nishikawa, Ryo
- Published
- 2021
- Full Text
- View/download PDF
6. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
- Author
-
Wakabayashi, Toshihiko, Natsume, Atsushi, Mizusawa, Junki, Katayama, Hiroshi, Fukuda, Haruhiko, Sumi, Minako, Nishikawa, Ryo, Narita, Yoshitaka, Muragaki, Yoshihiro, Maruyama, Takashi, Ito, Tamio, Beppu, Takaaki, Nakamura, Hideo, Kayama, Takamasa, Sato, Shinya, Nagane, Motoo, Mishima, Kazuhiko, Nakasu, Yoko, Kurisu, Kaoru, Yamasaki, Fumiyuki, Sugiyama, Kazuhiko, Onishi, Takanori, Iwadate, Yasuo, Terasaki, Mizuhiko, Kobayashi, Hiroyuki, Matsumura, Akira, Ishikawa, Eiichi, Sasaki, Hikaru, Mukasa, Akitake, Matsuo, Takayuki, Hirano, Hirofumi, Kumabe, Toshihiro, Shinoura, Nobusada, Hashimoto, Naoya, Aoki, Tomokazu, Asai, Akio, Abe, Tatsuya, Yoshino, Atsuo, Arakawa, Yoshiki, Asano, Kenichiro, Yoshimoto, Koji, Shibui, Soichiro, and Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)
- Published
- 2018
- Full Text
- View/download PDF
7. Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study.
- Author
-
Nagane, Motoo, Ichimura, Koichi, Onuki, Ritsuko, Narushima, Daichi, Honda-Kitahara, Mai, Satomi, Kaishi, Tomiyama, Arata, Arai, Yasuhito, Shibata, Tatsuhiro, Narita, Yoshitaka, Uzuka, Takeo, Nakamura, Hideo, Nakada, Mitsutoshi, Arakawa, Yoshiki, Ohnishi, Takanori, Mukasa, Akitake, Tanaka, Shota, Wakabayashi, Toshihiko, Aoki, Tomokazu, and Aoki, Shigeki
- Subjects
DISEASE progression ,DRUG efficacy ,EXPERIMENTAL design ,CLINICAL trials ,DNA ,METHYLTRANSFERASES ,GLIOMAS ,ANTINEOPLASTIC agents ,RNA ,MACROPHAGES ,TREATMENT effectiveness ,COMPARATIVE studies ,PRE-tests & post-tests ,TEMOZOLOMIDE ,DESCRIPTIVE statistics ,SURVIVAL analysis (Biometry) ,GENES ,BEVACIZUMAB ,TUMOR markers ,PATIENT safety ,EVALUATION - Abstract
Simple Summary: This was a multicenter, single-arm, phase II study comprising two protocol treatments. Patients were enrolled after craniotomy or biopsy and initiated the concurrent phase; oral daily temozolomide concomitant with radiation therapy during the first 6 weeks of treatment. Bevacizumab was intravenously administered every other week. The protocol-defined secondary therapy (i.e., BBP regimen) was given as bevacizumab monotherapy or in combination with other chemotherapeutic agents upon first progression or recurrence until further progression or unacceptable toxicity developed. The primary endpoint, the 2-year survival rate of the BBP group, was 27.0% and was unmet. Expression profiling using RNA sequencing identified that Cluster 2, enriched with the genes involved in macrophage or microglia activation, was associated with longer OS and PFS independent of the MGMT methylation status. We evaluated the efficacy and safety of bevacizumab beyond progression (BBP) in Japanese patients with newly diagnosed glioblastoma and explored predictors of response to bevacizumab. This phase II study evaluated a protocol-defined primary therapy by radiotherapy with concurrent and adjuvant temozolomide plus bevacizumab, followed by bevacizumab monotherapy, and secondary therapy (BBP: bevacizumab upon progression). Ninety patients received the protocol-defined primary therapy (BBP group, n = 25). Median overall survival (mOS) and median progression-free survival (mPFS) were 25.0 and 14.9 months, respectively. In the BBP group, in which O
6 -methylguanine-DNA methyltransferase (MGMT)-unmethylated tumors predominated, mOS and mPFS were 5.8 and 1.9 months from BBP initiation and 16.8 and 11.4 months from the initial diagnosis, respectively. The primary endpoint, the 2-year survival rate of the BBP group, was 27.0% and was unmet. No unexpected adverse events occurred. Expression profiling using RNA sequencing identified that Cluster 2, which was enriched with the genes involved in macrophage or microglia activation, was associated with longer OS and PFS independent of the MGMT methylation status. Cluster 2 was identified as a significantly favorable independent predictor for PFS, along with younger age and methylated MGMT. The novel expression classifier may predict the prognosis of glioblastoma patients treated with bevacizumab. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy.
- Author
-
Hosoya, Tomohiro, Takahashi, Masamichi, Davey, Calvin, Sese, Jun, Honda-Kitahara, Mai, Miyakita, Yasuji, Ohno, Makoto, Yanagisawa, Shunsuke, Omura, Takaki, Kawauchi, Daisuke, Ozeki, Yukie, Kikuchi, Miyu, Nakano, Tomoyuki, Yoshida, Akihiko, Igaki, Hiroshi, Matsushita, Yuko, Ichimura, Koichi, and Narita, Yoshitaka
- Subjects
METHYLGUANINE ,VOLUMETRIC analysis ,RECEIVER operating characteristic curves ,PYROSEQUENCING ,TEMOZOLOMIDE ,GLIOBLASTOMA multiforme ,METHYLATION - Abstract
The aim of the present study was to determine which individual or combined CpG sites among O
6 -methylguanine DNA methyltransferase CpG 74–89 in glioblastoma mainly affects the response to temozolomide resulting from CpG methylation using statistical analyses focused on the tumor volume ratio (TVR). We retrospectively examined 44 patients who had postoperative volumetrically measurable residual tumor tissue and received adjuvant temozolomide therapy for at least 6 months after initial chemoradiotherapy. TVR was defined as the tumor volume 6 months after the initial chemoradiotherapy divided by that before the start of chemoradiotherapy. Predictive values for TVR as a response to adjuvant therapy were compared among the averaged methylation percentages of individual or combined CpGs using the receiver operating characteristic curve. Our data revealed that combined CpG 78 and 79 showed a high area under the curve (AUC) and a positive likelihood ratio and that combined CpG 76–79 showed the highest AUC among all combinations. AUCs of consecutive CpG combinations tended to be higher for CpG 74–82 in exon 1 than for CpG 83–89 in intron 1. In conclusion, the methylation status at CpG sites in exon 1 was strongly associated with TVR reduction in glioblastoma. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas
- Author
-
Ohno, Makoto, Narita, Yoshitaka, Miyakita, Yasuji, Matsushita, Yuko, Yoshida, Akihiko, Fukushima, Shintaro, Ichimura, Koichi, and Shibui, Soichiro
- Published
- 2013
- Full Text
- View/download PDF
10. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss
- Author
-
Arita, Hideyuki, Narita, Yoshitaka, Fukushima, Shintaro, Tateishi, Kensuke, Matsushita, Yuko, Yoshida, Akihiko, Miyakita, Yasuji, Ohno, Makoto, Collins, V. Peter, Kawahara, Nobutaka, Shibui, Soichiro, and Ichimura, Koichi
- Published
- 2013
- Full Text
- View/download PDF
11. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)
- Author
-
Shibui, Soichiro, Narita, Yoshitaka, Mizusawa, Junki, Beppu, Takaaki, Ogasawara, Kuniaki, Sawamura, Yutaka, Kobayashi, Hiroyuki, Nishikawa, Ryo, Mishima, Kazuhiko, Muragaki, Yoshihiro, Maruyama, Takashi, Kuratsu, Junichi, Nakamura, Hideo, Kochi, Masato, Minamida, Yoshio, Yamaki, Toshiaki, Kumabe, Toshihiro, Tominaga, Teiji, Kayama, Takamasa, Sakurada, Kaori, Nagane, Motoo, Kobayashi, Keiichi, Nakamura, Hirohiko, Ito, Tamio, Yazaki, Takahito, Sasaki, Hikaru, Tanaka, Katsuyuki, Takahashi, Hideaki, Asai, Akio, Todo, Tomoki, Wakabayashi, Toshihiko, Takahashi, Jun, Takano, Shingo, Fujimaki, Takamitsu, Sumi, Minako, Miyakita, Yasuji, Nakazato, Yoichi, Sato, Akihiro, Fukuda, Haruhiko, and Nomura, Kazuhiro
- Published
- 2013
- Full Text
- View/download PDF
12. Management of glioblastoma in an NF1 patient with moyamoya syndrome: a case report
- Author
-
Arita, Hideyuki, Narita, Yoshitaka, Ohno, Makoto, Miyakita, Yasuji, Okita, Yoshiko, Ide, Takafumi, and Shibui, Soichiro
- Published
- 2013
- Full Text
- View/download PDF
13. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status
- Author
-
Ohno, Makoto, Narita, Yoshitaka, Miyakita, Yasuji, Okita, Yoshiko, Matsushita, Yuko, Yoshida, Akihiko, Fukushima, Shintaro, Ichimura, Koichi, Kayama, Takamasa, and Shibui, Soichiro
- Published
- 2012
- Full Text
- View/download PDF
14. Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma
- Author
-
Nishikawa, Ryo, Sugiyama, Tatsuya, Narita, Yoshitaka, Furnari, Frank, Cavenee, Webster K., and Matsutani, Masao
- Published
- 2004
- Full Text
- View/download PDF
15. Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme
- Author
-
Narita, Yoshitaka, Asai, Akio, Kuchino, Yoshiyuki, and Kirino, Takaaki
- Published
- 2000
- Full Text
- View/download PDF
16. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
- Author
-
Arakawa, Yoshiki, Sasaki, Keita, Mineharu, Yohei, Uto, Megumi, Mizowaki, Takashi, Mizusawa, Junki, Sekino, Yuta, Ono, Tomohiro, Aoyama, Hidefumi, Satomi, Kaishi, Ichimura, Koichi, Kinoshita, Manabu, Ohno, Makoto, Ito, Yoshinori, Nishikawa, Ryo, Fukuda, Haruhiko, Nishimura, Yasumasa, Narita, Yoshitaka, and Brain Tumor Study Group and Radiation Therapy Study Group of the Japan Clinical Oncology Group
- Subjects
OLDER patients ,DIAGNOSIS ,TEMOZOLOMIDE ,GLIOBLASTOMA multiforme ,KARNOFSKY Performance Status ,CHEMORADIOTHERAPY - Abstract
Background: The current standard treatment for elderly patients with newly diagnosed glioblastoma is surgery followed by short-course radiotherapy with temozolomide. In recent studies, 40 Gy in 15 fractions vs. 60 Gy in 30 fractions, 34 Gy in 10 fractions vs. 60 Gy in 30 fractions, and 40 Gy in 15 fractions vs. 25 Gy in 5 fractions have been reported as non-inferior. The addition of temozolomide increased the survival benefit of radiotherapy with 40 Gy in 15 fractions. However, the optimal regimen for radiotherapy plus concomitant temozolomide remains unresolved.Methods: This multi-institutional randomized phase III trial was commenced to confirm the non-inferiority of radiotherapy comprising 25 Gy in 5 fractions with concomitant (150 mg/m2/day, 5 days) and adjuvant temozolomide over 40 Gy in 15 fractions with concomitant (75 mg/m2/day, every day from first to last day of radiation) and adjuvant temozolomide in terms of overall survival (OS) in elderly patients with newly diagnosed glioblastoma. A total of 270 patients will be accrued from 51 Japanese institutions in 4 years and follow-up will last 2 years. Patients 71 years of age or older, or 71-75 years old with resection of less than 90% of the contrast-enhanced region, will be registered and randomly assigned to each group with 1:1 allocation. The primary endpoint is OS, and the secondary endpoints are progression-free survival, frequency of adverse events, proportion of Karnofsky performance status preservation, and proportion of health-related quality of life preservation. The Japan Clinical Oncology Group Protocol Review Committee approved this study protocol in April 2020. Ethics approval was granted by the National Cancer Center Hospital Certified Review Board. Patient enrollment began in August 2020.Discussion: If the primary endpoint is met, short-course radiotherapy comprising 25 Gy in 5 fractions with concomitant and adjuvant temozolomide will be a standard of care for elderly patients with newly diagnosed glioblastoma.Trial Registration: Registry number: jRCTs031200099 . Date of Registration: 27/Aug/2020. Date of First Participant Enrollment: 4/Sep/2020. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death.
- Author
-
Kawauchi, Daisuke, Takahashi, Masamichi, Satomi, Kaishi, Yamamuro, Shun, Kobayashi, Tatsuya, Uchida, Eita, Honda‐Kitahara, Mai, Narita, Yoshitaka, Iwadate, Yasuo, Ichimura, Koichi, and Tomiyama, Arata
- Abstract
Glioblastoma (GBM) is the most common, but extremely malignant, brain tumor; thus, the development of novel therapeutic strategies for GBMs is imperative. Many tyrosine kinase inhibitors (TKIs) have been approved for various cancers, yet none has demonstrated clinical benefit against GBM. Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) that is confirmed only during the embryonic development period in humans. In addition, various ALK gene alterations are known to act as powerful oncogenes and therapeutic targets in various tumors. The antitumor activity of various TKIs was tested against three human GBM cell lines (U87MG, LN229, and GSC23), which expressed substantially low ALK levels; second‐generation ALK inhibitors, alectinib and ceritinib, effectively induced GBM cell death. In addition, treatment with either alectinib or ceritinib modulated the activation of various molecules downstream of RTK signaling and induced caspase‐dependent/‐independent cell death mainly by inhibiting signal transducer and activator of transcription 3 activation in human GBM cells. In addition, alectinib and ceritinib also showed antitumor activity against a U87MG cell line with acquired temozolomide resistance. Finally, oral administration of alectinib and ceritinib prolonged the survival of mice harboring intracerebral GBM xenografts compared with controls. These results suggested that treatment with the second‐generation ALK inhibitors, alectinib and ceritinib, might serve as a potent therapeutic strategy against GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR.
- Author
-
Miki, Shunichiro, Satomi, Kaishi, Ohno, Makoto, Matsushita, Yuko, Kitahara, Mai, Miyakita, Yasuji, Takahashi, Masamichi, Matsuda, Masahide, Ishikawa, Eiichi, Matsumura, Akira, Yoshida, Akihiko, Narita, Yoshitaka, and Ichimura, Koichi
- Abstract
Telomerase reverse transcriptase promoter (TERTp) hotspot mutations are the most frequent mutations in primary glioblastomas (GBM). Previous studies have shown that the combination of TERTp and isocitrate dehydrogenase (IDH) status may serve as a useful diagnostic marker for oligodendroglioma and glioblastoma. In oligodendrogliomas, TERTp and IDH mutations, along with the 1p/19q codeletion, usually coexist and are likely to be founder mutations. However, in contrast to oligodendroglioma, the role of the TERTp status in GBM remains obscure. Here, we used Sanger sequencing, pyrosequencing, and digital PCR (dPCR) to examine the TERTp status in 15 pairs of frozen tissue samples from primary and recurrent IDH wild-type GBM, all of which were operated in a single institute. We showed that the TERTp status was stable between primary and recurrent GBM but this consistency was only detected by dPCR. The results suggest that dPCR is a powerful, highly sensitive tool to detect TERTp mutations, especially in a mixed cell population (e.g., a recurrent GBM tissue) where earlier treatment may have grossly altered the tumor microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.
- Author
-
Takahashi, Masamichi, Miki, Shunichiro, Fujimoto, Kenji, Fukuoka, Kohei, Matsushita, Yuko, Maida, Yoshiko, Yasukawa, Mami, Hayashi, Mitsuhiro, Shinkyo, Raku, Kikuchi, Kiyomi, Mukasa, Akitake, Nishikawa, Ryo, Tamura, Kenji, Narita, Yoshitaka, Hamada, Akinobu, Masutomi, Kenkichi, and Ichimura, Koichi
- Abstract
Glioblastoma is one of the most devastating human malignancies for which a novel efficient treatment is urgently required. This pre–clinical study shows that eribulin, a specific inhibitor of telomerase reverse transcriptase (TERT)‐RNA‐dependent RNA polymerase, is an effective anticancer agent against glioblastoma. Eribulin inhibited the growth of 4 TERT promoter mutation‐harboring glioblastoma cell lines in vitro at subnanomolar concentrations. In addition, it suppressed the growth of glioblastoma cells transplanted subcutaneously or intracerebrally into mice, and significantly prolonged the survival of mice harboring brain tumors at a clinically equivalent dose. A pharmacokinetics study showed that eribulin quickly penetrated brain tumors and remained at a high concentration even when it was washed away from plasma, kidney or liver 24 hours after intravenous injection. Moreover, a matrix‐assisted laser desorption/ionization mass spectrometry imaging analysis revealed that intraperitoneally injected eribulin penetrated the brain tumor and was distributed evenly within the tumor mass at 1 hour after the injection whereas only very low levels of eribulin were detected in surrounding normal brain. Eribulin is an FDA‐approved drug for refractory breast cancer and can be safely repositioned for treatment of glioblastoma patients. Thus, our results suggest that eribulin may serve as a novel therapeutic option for glioblastoma. Based on these data, an investigator‐initiated registration‐directed clinical trial to evaluate the safety and efficacy of eribulin in patients with recurrent GBM (UMIN000030359) has been initiated. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Bevacizumab for glioblastoma.
- Author
-
Narita, Yoshitaka
- Subjects
- *
BEVACIZUMAB , *ANTINEOPLASTIC agents , *GLIOBLASTOMA multiforme treatment , *GLIOBLASTOMA multiforme , *GLIOMA treatment , *DISEASE risk factors - Abstract
Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic findings in many patients with malignant gliomas, including glioblastoma. Although the addition of BV to the conventional standard therapy (chemoradiotherapy with temozolomide) for newly diagnosed glioblastoma prolonged the progression-free survival time and the performance status of patients, it failed to extend overall survival time. However, more than 50% of glioblastoma patients show Karnofsky performance status ≤70 at initial presentation; therefore, BV should be used to improve or maintain their performance status as an initial treatment. Most of the adverse events of BV, except hypertension and proteinuria, occur as complications of glioblastoma, and explanation of the advantages and disadvantages of BV administration to patients is important. Herein, the efficacy, safety, and challenges of using BV for treating glioblastoma were reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Revisiting TP 53 Mutations and Immunohistochemistry-A Comparative Study in 157 Diffuse Gliomas.
- Author
-
Takami, Hirokazu, Yoshida, Akihiko, Fukushima, Shintaro, Arita, Hideyuki, Matsushita, Yuko, Nakamura, Taishi, Ohno, Makoto, Miyakita, Yasuji, Shibui, Soichiro, Narita, Yoshitaka, and Ichimura, Koichi
- Subjects
GLIOMAS ,IMMUNOHISTOCHEMISTRY ,NUCLEOTIDE sequencing ,NERVOUS system tumors - Abstract
The association between p53 immunohistochemistry and TP 53 mutation status has been controversial. The present study aims to re-evaluate the efficacy of p53 immunohistochemistry to predict the mutational status of TP 53. A total of 157 diffuse gliomas ( World Health Organization grades II- IV) were assessed by exon-by-exon DNA sequencing from exon 4 through 10 of TP 53 using frozen tissue samples. Immunohistochemistry with a p53 antibody ( DO-7) on paired formalin-fixed paraffin-embedded materials was assessed for the extent and intensity of reactivity in all cases. A total of 72 mutations were detected in 66 samples. They included 60 missense mutations, five nonsense mutations, four deletions and three alterations in the splicing sites. A receiver operating characteristic curve analysis revealed that strong p53 immunoreactivity in more than 10% of cells provided the most accurate prediction of mutation. Using this cutoff value, 52 of 55 immunopositive cases harbored a mutation, whereas only 14 of 102 immunonegative cases showed mutations, sensitivity and specificity being 78.8% and 96.7%. Tumors with frameshift mutations frequently showed negative immunostaining. Staining interpretation by an independent observer yielded comparable accuracy. We thus propose p53 immunohistochemistry as a moderately sensitive and highly specific marker to predict TP 53 mutation. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
22. A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy.
- Author
-
Fukushima, Shintaro, Narita, Yoshitaka, Miyakita, Yasuji, Ohno, Makoto, Takizawa, Tsuguto, Takusagawa, Yutaka, Mori, Masaya, Ichimura, Koichi, Tsuda, Hitoshi, and Shibui, Soichiro
- Subjects
- *
TUMORS , *PATHOLOGY , *MEDICAL radiology , *SURGICAL excision , *GLIOBLASTOMA multiforme - Abstract
Glioblastoma ( GBM) is the most common malignant CNS neoplasm, the prognosis of which remains poor even after multidisciplinary treatment. The 5-year overall survival rate of GBM is less than 10% and has remained unchanged for more than 50 years. Because GBM patients rarely survive over a decade, only very few cases of delayed complications caused by therapy have been reported. Here, we report the case of a 24-year-old man who is still alive 21 years after surgical resection and chemoradiotherapy for GBM. This patient developed a cavernous angioma 19 years after the initial surgery as a delayed complication of radiotherapy. The diagnosis of the initial tumor was confirmed by histopathological review, which indicated that the tumor had immunohistochemical and genetic profiles consistent with GBM. Long-term survival in the case of this GBM patient likely resulted from a combination of factors, including hypermethylation of the MGMT ( O6-methyl guanine methyl transferase) CpG island, young age at diagnosis, good performance status, and complete surgical resection of the tumor. To the best of our knowledge, this case report describes one of the longest-surviving GBM patients and is the first on radiation-induced cavernous angioma in a GBM patient. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. A case of unclassified high-grade glioma with polar spongioblastoma pattern.
- Author
-
Fukushima, Shintaro, Narita, Yoshitaka, Shinomiya, Aya, Ohno, Makoto, Miyakita, Yasuji, Okita, Yoshiko, Hanakawa, Kazuo, Ide, Takafumi, Kayama, Takamasa, Shibui, Soichiro, and Tsuda, Hitoshi
- Subjects
- *
GLIOMA treatment , *GLIOBLASTOMA multiforme , *MICROCIRCULATION disorders , *CEREBROSPINAL fluid , *ASTROCYTOMAS , *IMMUNOHISTOCHEMISTRY , *CELL proliferation , *THERAPEUTICS - Abstract
Primitive polar spongioblastoma was first described by Russell and Cairns in 1947. However, the polar spongioblastoma pattern is often seen in many neuroepithelial tumors, and this category was deleted in the previous World Health Organization (WHO) classification. In 2010, Nagaishi et al. reported on a case involving a neuroepithelial tumor with the typical histological pattern of polar spongioblastoma and suggested that this tumor might not be suited to any of the neuroepithelial tumors in the current WHO classification. We report on an autopsy case involving an unclassified high-grade glioma with polar spongioblastoma pattern that was very similar to the case described by Nagaishi et al. A 44-year-old man who presented with a headache exhibited a tumor of the right frontal lobe on MRI. Histological diagnosis of the tumor obtained by gross total resection was high-grade glioma, which was composed of the parallel palisading of spindle tumor cells expressing GFAP, without microvascular proliferation (MVP) and necrosis. Conventional chemoradiotherapy was performed, but the case was complicated by cerebrospinal fluid (CSF) dissemination that resulted in multiple extraneural metastases through systemic diversionary CSF shunting. Finally, the patient died approximately 13 months after the initial treatment. Both the cerebral and Douglas pouch tumors that were obtained at autopsy were diagnosed as typical glioblastomas, and they were composed of the proliferation of atypical astrocytes with MVP and pseudopalisading necrosis without the formation of rhythmic palisading. Although the histological findings were different from that of the first operation, immunohistochemical and genetic profiles demonstrated almost the same results. This tumor was not classified as a typical glioblastoma by the initial findings, but it had the nature of a glioblastoma. These findings suggest that the tumor might be classified as a new subset of glioblastoma called glioblastoma with polar spongioblastoma pattern. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
24. In Vivo Study of the Efficacy and Safety of 5-Aminolevulinic Radiodynamic Therapy for Glioblastoma Fractionated Radiotherapy.
- Author
-
Takahashi, Junko, Nagasawa, Shinsuke, Doi, Motomichi, Takahashi, Masamichi, Narita, Yoshitaka, Yamamoto, Junkoh, Ikemoto, Mitsushi J., and Iwahashi, Hitoshi
- Subjects
IONIZING radiation ,GLIOBLASTOMA multiforme ,GLIOMAS ,OVERALL survival ,LABORATORY mice ,SKIN - Abstract
To treat malignant glioma, standard fractionated radiotherapy (RT; 60 Gy/30 fractions over 6 weeks) was performed post-surgery in combination with temozolomide to improve overall survival. Malignant glioblastoma recurrence rate is extremely high, and most recurrent tumors originate from the excision cavity in the high-dose irradiation region. In our previous study, protoporphyrin IX physicochemically enhanced reactive oxygen species generation by ionizing radiation and combined treatment with 5-aminolevulinic acid (5-ALA) and ionizing radiation, while radiodynamic therapy (RDT) improved tumor growth suppression in vivo in a melanoma mouse model. We examined the effect of 5-ALA RDT on the standard fractionated RT protocol using U251MG- or U87MG-bearing mice. 5-ALA was orally administered at 60 or 120 mg/kg, 4 h prior to irradiation. In both models, combined treatment with 5-ALA slowed tumor progression and promoted regression compared to treatment with ionizing radiation alone. The standard fractionated RT protocol of 60 Gy in 30 fractions with oral administration of 120 and 240 mg/kg 5-ALA, the human equivalent dose of photodynamic diagnosis, revealed no significant increase in toxicity to normal skin or brain tissue compared to ionizing radiation alone. Thus, RDT is expected to enhance RT treatment of glioblastoma without severe toxicity under clinically feasible conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 Activation.
- Author
-
Kobayashi, Tatsuya, Miyazaki, Makoto, Sasaki, Nobuyoshi, Yamamuro, Shun, Uchida, Eita, Kawauchi, Daisuke, Takahashi, Masamichi, Otsuka, Yohei, Kumagai, Kosuke, Takeuchi, Satoru, Toyooka, Terushige, Otani, Naoki, Wada, Kojiro, Narita, Yoshitaka, Yamaguchi, Hideki, Muragaki, Yoshihiro, Kawamata, Takakazu, Mori, Kentaro, Ichimura, Koichi, and Tomiyama, Arata
- Subjects
CELL death ,CELL migration ,GLIOMAS ,IMMUNOBLOTTING ,MICROBIOLOGICAL assay ,PHOTOCHEMOTHERAPY ,STEM cells ,PHENOTYPES ,MITOGEN-activated protein kinases ,CASPASES ,CELL survival ,IN vitro studies - Abstract
Simple Summary: The molecular machineries regulating resistance against photodynamic therapy (PDT) using talaporfin sodium (NPe6) (NPe6-PDT) in glioblastomas (GBM)s and mechanisms underlying the changes in GBM phenotypes following NPe6-PDT remain unknown. Herein, we established an in vitro NPe6-mediated PDT model using human GBM cell lines. NPe6-PDT induced both caspase-dependent and -independent GBM cell death in a NPe6 dose-dependent manner. Moreover, treatment with poly (ADP-ribose) polymerase inhibitor blocked NPe6-PDT-triggered caspase-independent GBM cell death. Next, it was revealed resistance to re-NPe6-PDT, migration, and invasion of GBM cells that survived following NPe6-PDT (NPe6-PDT-R cells) were enhanced. Immunoblotting of NPe6-PDT-R revealed that only ERK1/2 activation exhibited the same trend as migration. Importantly, treatment with the MEK1/2 inhibitor trametinib reversed resistance against re-NPe6-PDT and suppressed the enhanced migration and invasion of NPe6-PDT-R cells. Overall, enhanced ERK1/2 activation is suggested as a key regulator of elevated malignant phenotypes of GBM cells surviving NPe6-PDT. To manage refractory and invasive glioblastomas (GBM)s, photodynamic therapy (PDT) using talaporfin sodium (NPe6) (NPe6-PDT) was recently approved in clinical practice. However, the molecular machineries regulating resistance against NPe6-PDT in GBMs and mechanisms underlying the changes in GBM phenotypes following NPe6-PDT remain unknown. Herein, we established an in vitro NPe6-mediated PDT model using human GBM cell lines. NPe6-PDT induced GBM cell death in a NPe6 dose-dependent manner. However, this NPe6-PDT-induced GBM cell death was not completely blocked by the pan-caspase inhibitor, suggesting NPe6-PDT induces both caspase-dependent and -independent cell death. Moreover, treatment with poly (ADP-ribose) polymerase inhibitor blocked NPe6-PDT-triggered caspase-independent GBM cell death. Next, it was also revealed resistance to re-NPe6-PDT of GBM cells and GBM stem cells survived following NPe6-PDT (NPe6-PDT-R cells), as well as migration and invasion of NPe6-PDT-R cells were enhanced. Immunoblotting of NPe6-PDT-R cells to assess the behavior of the proteins that are known to be stress-induced revealed that only ERK1/2 activation exhibited the same trend as migration. Importantly, treatment with the MEK1/2 inhibitor trametinib reversed resistance against re-NPe6-PDT and suppressed the enhanced migration and invasion of NPe6-PDT-R cells. Overall, enhanced ERK1/2 activation is suggested as a key regulator of elevated malignant phenotypes of GBM cells surviving NPe6-PDT and is therefore considered as a potential therapeutic target against GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Evidence-based recommendations on categories for extent of resection in diffuse glioma.
- Author
-
Karschnia, Philipp, Vogelbaum, Michael A., van den Bent, Martin, Cahill, Daniel P., Bello, Lorenzo, Narita, Yoshitaka, Berger, Mitchel S., Weller, Michael, and Tonn, Joerg-Christian
- Subjects
- *
OPERATIVE surgery , *GLIOMAS , *EVIDENCE-based medicine , *MEDICAL protocols , *CANCER patients , *TREATMENT effectiveness , *CONCEPTUAL structures , *TERMS & phrases - Abstract
Surgical resection represents the standard of care in diffuse glioma, and more extensive tumour resection appears to be associated with favourable outcome. Up to now, terminology to describe extent of resection has been inconsistently applied across clinical trials which hampers comparative analysis of cohorts between different studies. Based on a comprehensive literature review, we developed evidence-based expert recommendations on categories for extent of resection. Recommendations are formulated for the categories 'biopsy', 'partial resection', 'subtotal resection', 'near total resection', 'complete resection' and 'supramaximal resection'. Definitions rest on reduction of contrast- and non–contrast-enhancing tumour in glioblastoma, and on reduction of T2/FLAIR-hyperintense tumour in gliomas WHO grade 2 or 3. Both relative reduction of tumour volume (in percentage) as a measurement of surgical efficacy and absolute residual tumour volume (in cm3) as a measurement of remaining tumour burden are incorporated into the categories for extent of resection. Class of evidence for the proposed categories ranges from class IIB to IV. Limitations of the suggested categories are discussed. The proposed categories on extent of resection offer a framework to standardize nomenclature based on previous studies, and will need to be evaluated in prospective, molecularly well-defined cohorts. Our categories may eventually help as a stratification factor for future clinical trials. • Nomenclature to describe extent of resection in diffuse glioma is inconsistent. • Categories are formulated based on an extensive literature review. • Definitions rest on relative reduction of tumour and absolute residual tumour. • Class of evidence for the proposed categories ranges from class IIB-IV. • Our categories offer a framework to standardize nomenclature in diffuse glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft.
- Author
-
Yamamoto, Yutaro, Tomiyama, Arata, Sasaki, Nobuyoshi, Yamaguchi, Hideki, Shirakihara, Takuya, Nakashima, Katsuhiko, Kumagai, Kosuke, Takeuchi, Satoru, Toyooka, Terushige, Otani, Naoki, Wada, Kojiro, Narita, Yoshitaka, Ichimura, Koichi, Sakai, Ryuichi, Namba, Hiroki, and Mori, Kentaro
- Subjects
- *
PHYSIOLOGICAL effects of cholesterol , *CELL death , *CASPASES , *DEATH receptors , *MEMBRANE lipids , *DRUG resistance , *IMMUNOMODULATORS - Abstract
Development of resistance against temozolomide (TMZ) in glioblastoma (GBM) after continuous treatment with TMZ is one of the critical problems in clinical GBM therapy. Intracellular cholesterol regulates cancer cell biology, but whether intracellular cholesterol is involved in TMZ resistance of GBM cells remains unclear. The involvement of intracellular cholesterol in acquired resistance against TMZ in GBM cells was investigated. Intracellular cholesterol levels were measured in human U251 MG cells with acquired TMZ resistance (U251-R cells) and TMZ-sensitive control U251 MG cells (U251-Con cells), and found that the intracellular cholesterol level was significantly lower in U251-R cells than in U251-Con cells. In addition, treatment by intracellular cholesterol remover, methyl-beta cyclodextrin (MβCD), or intracellular cholesterol inducer, soluble cholesterol (Chol), regulated TMZ-induced U251-Con cell death in line with changes in intracellular cholesterol level. Involvement of death receptor 5 (DR5), a death receptor localized in the plasma membrane, was evaluated. TMZ without or with MβCD and/or Chol caused accumulation of DR5 into the plasma membrane lipid raft and formed a complex with caspase-8, an extrinsic caspase cascade inducer, reflected in the induction of cell death. In addition, treatment with caspase-8 inhibitor or knockdown of DR5 dramatically suppressed U251-Con cell death induced by combination treatment with TMZ, MβCD, and Chol. Combined treatment of Chol with TMZ reversed the TMZ resistance of U251-R cells and another GBM cell model with acquired TMZ resistance, whereas clinical antihypercholesterolemia agents at physiological concentrations suppressed TMZ-induced cell death of U251-Con cells. These findings suggest that intracellular cholesterol level affects TMZ treatment of GBM mediated via a DR5-caspase-8 mechanism. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.